Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial in Overall Progressive Multiple Sclerosis Study Population and Across Subtypes, Reinforcing the Drug's Neuroprotective Potential and Ability to Slow Disease Progression Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 New... Read More

At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW Vidofludimus Calcium Continues to Demonstrate Favorable Safety and Tolerability Profile; Long-Term Data Now Available up to 5.5 Years NEW YORK , June 24, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small... Read More

Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 Additional Data from Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Further Supports the Recently Released Positive Top-Line Results and Further Underlines Vidofludimus Calcium's Neuroprotective Potential New CALLIPER Data Regarding Time to 24-Week Confirmed Disability... Read More

NEW YORK , June 3, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced underwritten public offering of (i) pre-funded warrants to purchase shares of common stock (the "Pre-Funded Warrants"),... Read More

NEW YORK , June 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor, scientific and industry conferences in June: June 3-5: Jefferies Healthcare Conference. Daniel Vitt , Ph.D., Chief Executive Officer of Immunic,... Read More

NEW YORK , May 29, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock (the "Pre-Funded Warrants"), (ii) series A... Read More

NEW YORK , May 28, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has commenced an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock, (ii) Series A warrants to purchase shares... Read More

NEW YORK , May 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in May: May 3-6: Digestive Disease Week (DDW). Two abstracts discussing Immunic's phase 1/ 1b clinical trial of IMU-856,... Read More

Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Primary Progressive Multiple Sclerosis Showed Consistent Reduction of Disability Worsening in Subpopulations Without Inflammatory Lesions at Baseline in Overall Study Population; Reduced Relative Risk of 24-Week Confirmed Disability... Read More

NEW YORK , April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced registered direct offering of 5,666,667 shares of its common stock at a price of $0.90 per share, led by Aberdeen... Read More

NEW YORK , April 9, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of a registered direct offering of 5,666,667 shares of its common stock at the market under Nasdaq rules at a price of $0.90 per share, led by... Read More

NEW YORK , April 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in April: April 5-9 : American Academy of Neurology (AAN) 2025 Annual Meeting. Members of Immunic's management, medical... Read More

NEW YORK , March 3, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March: March 4-7 : 34 th Annual Meeting of the Society for Virology. Two abstracts have been accepted for abstract... Read More

Vidofludimus Calcium's Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activations in Preclinical Models Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April NEW YORK , Feb. 26, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered,... Read More

New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Post Hoc Analysis of Patients From Phase 1b Clinical Trial in Celiac Disease Dose-Dependent Reduction of Body Weight Gain and Food Consumption Observed in Preclinical Study Webcast to be Held Today, February 20 at 8:00 am ET NEW YORK , Feb.... Read More

NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February: February 10-11 : BIO CEO & Investor Conference 2025. Daniel Vitt , Ph.D., Chief Executive Officer of... Read More

Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 Strengthened Management Team and Board of Directors with Key Hires Announced a Three-Tranche Private Placement Totaling... Read More

NEW YORK , Nov. 26, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt , Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 5, 2024 , at 11:30 am ET , during the Piper Sandler 36th Annual... Read More

Includes Phase 1 Data in Healthy Human Subjects and Phase 1b Data in Celiac Disease Patients NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the data from its phase 1/ 1b clinical trial of IMU-856, an orally available and... Read More

Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should Continue as Planned Ongoing, Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Remain on Track Top-Line Data from Phase 2 CALLIPER Trial Expected in April 2025... Read More

Webcast to be Held at 8:00 am ET on November 7, 2024 NEW YORK , Oct. 31, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2024 , including a corporate update, on... Read More

NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry, scientific and investor conferences in November: November 4-6 : BIO-Europe. Members of Immunic's management, business development and investor... Read More

Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermined Futility Criteria Have Not Been Met IDMC Also Recommended Continuing Trial without Changes, Including no Need for a Potential Upsizing ENSURE Program Remains on Track to be Completed in 2026 Webcast to be Held Today, October 22 , at 8:00 am ET NEW YORK , Oct. 22, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX),... Read More

Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All Progressive Multiple Sclerosis Subtypes Clinical Signal Shown for Vidofludimus Calcium on Post COVID Fatigue May Be Related to Epstein-Barr Virus Reactivation; Preventing This Reactivation May Contribute to Fatigue... Read More

Investigator Study Sponsored by Goethe University Frankfurt ( Germany ), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided by Immunic In Addition to Post COVID Readouts, Study Designed to Deliver Important Data on the Activity of Vidofludimus Calcium Suppressing Epstein-Barr Virus Reactivation and Related Fatigue Symptoms; Third-Party Research Identified Epstein-Barr Virus Reactivation as... Read More

NEW YORK , Aug. 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following scientific and investor conferences in September: September 10 :... Read More

Jason Tardio , Experienced Multiple Sclerosis Drug Commercialization Executive, Formerly with Novartis and Biogen, Appointed Chief Operating Officer and President Strengthened Board of Directors with Appointment of Simona Skerjanec , Senior Pharmaceutical Executive and Thought Leader in Brain Health Ongoing, Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple... Read More

Webcast to be Held at 8:00 am ET on August 8, 2024 NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the second quarter ended June 30, 2024 , including a corporate update, on... Read More

Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® NEW YORK , July 24, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic... Read More

Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic Werner Gladdines, Current Vice President, Program Management & Clinical Development Operations, Promoted to Chief Development Officer NEW YORK , July 9, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies... Read More

NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and scientific conferences in June: June 3-6 : BIO International Convention 2024. Jessica Breu , Vice President Investor Relations and... Read More

Substantially Bolstered Balance Sheet Through a Three-Tranche Private Placement Totaling Up to $240 Million , Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche Received Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis; Multilayered Intellectual Property Strategy Provides Protection Into 2041 in the United States Twin Phase 3 ENSURE Trials in Relapsing... Read More

NEW YORK , May 6, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May: May 12-14 and 21-22: Bio€quity Europe 2024. Jessica Breu , Vice President Investor Relations and Communications at... Read More

Webcast to be Held at 8:00 am ET on May 8, 2024 NEW YORK , May 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the first quarter ended March 31, 2024 , including a corporate update, on Wednesday,... Read More

30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Compared to Pooled Placebo at 24 Weeks Improvements in Serum Neurofilament Light Chain Consistent with Recently Announced Interim Phase 2 CALLIPER Data in Progressive Multiple Sclerosis Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis... Read More

NEW YORK , April 4, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following investor conferences in April: April 9 : Immunic's MS R&D Day . Management... Read More

Patent Will Also Cover a Related Method of Production of the Material Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis Multilayered Intellectual Property Strategy Provides Protection Into 2041 in the United States and Into 2039 Internationally, Unless Extended Further NEW YORK , March 20, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline... Read More

NEW YORK , March 7, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in March: March 11-13 : Leerink Partners Global Biopharma Conference . Daniel Vitt , Ph.D., Chief Executive Officer and... Read More

NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data from the company's phase 2 CALLIPER and CALVID-1 clinical trials of lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in... Read More

Significantly Strengthened Balance Sheet in January 2024 with Execution of Three-Tranche Private Placement of up to $240 Million , Extending Cash Runway Into the Third Quarter of 2025 Based on Initial $80 Million Tranche Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis, Consistent Across the Entire Progressive Multiple Sclerosis Population and All Subtypes; Top-Line... Read More

Webcast to be Held at 8:00 am ET on February 22, 2024 NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2023 , including a corporate... Read More

NEW YORK , Feb. 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February: February 8 : BioCapital Europe 2024 . Daniel Vitt , Ph.D., Chief Executive Officer and President of Immunic,... Read More

Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis, Consistent Across the Entire Progressive Multiple Sclerosis Population and All Subtypes Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing Improvements in Gut Health Demonstrated in Phase 1b Clinical Trial of IMU-856 in Celiac Disease Expanded Vidofludimus Calcium Patent Portfolio with Additional New Patents... Read More

NEW YORK , Jan. 5, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) ("Immunic" or the "Company"), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced it has entered into a securities purchase agreement with select accredited investors to purchase shares of common stock (or pre-funded warrants in lieu... Read More

Fundamental New Patent Covers Treatment of Multiple Sclerosis Into 2038 and Beyond Third U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis Multilayered Intellectual Property Strategy Provides Protection Into 2041 in the U.S. and Into 2038 Internationally, Unless Extended Further Adds on Recently Allowed U.S. Patent Protecting Specific Dose Strength for Relapsing Multiple Sclerosis Treatment NEW YORK ,... Read More

Positive Interim Analysis from Phase 2 CALLIPER Trial Showed Improvements in Serum Neurofilament Light Chain for Vidofludimus Calcium, Consistent Throughout the Overall Progressive Multiple Sclerosis Population and All Subtypes Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts Bolsters Multilayered Intellectual Property Position $59.7 Million... Read More

Webcast to be Held at 8:00 am ET on November 14, 2023 NEW YORK , Nov. 7, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2023 , including a corporate update, on... Read More

NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/391,442, entitled, "Treatment of Multiple Sclerosis... Read More

NEW YORK , Oct. 26, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in November: November 2-5 : Association of European Coeliac Societies (AOECS) 35th General Assembly Conference 2023.... Read More

NEW YORK , Oct. 16, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data from the company's phase 2 CALDOSE-1 trial of vidofludimus calcium (IMU-838) in an oral presentation at the United European Gastroenterology Week (UEGW) 2023,... Read More

NEW YORK , Oct. 15, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data from the company's phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), in... Read More

Improvement in Serum Neurofilament Light Chain (NfL) Observed in Both Treatment Arms of Vidofludimus Calcium Over Placebo NfL Effect Consistent With Recently Released Data from Separate, Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis NEW YORK , Oct. 11, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small... Read More

24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – NfL Effect in Non-Active Subpopulation Reinforces Vidofludimus Calcium's Neuroprotective Potential Brain Volume Data of the Full 467 CALLIPER Patient Cohort Expected in April 2025 Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing... Read More

NEW YORK , Oct. 4, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific conferences in October: October 11-13: MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting. Robert J. Fox , MD, Staff Neurologist, Mellen Center... Read More

NEW YORK , Sept. 6, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in September: September 13-14 : BioPharm America™. Patrick Walsh , Chief Business Officer of Immunic, will attend this... Read More

Unblinded Interim Biomarker Analysis Expected in the Fall of 2023 Full Data Readout Expected in April 2025 NEW YORK , Aug. 17, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the completion of enrollment of its phase 2 CALLIPER trial of lead asset,... Read More

Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal Diseases by Promoting Regeneration of Bowel Architecture Interim Results From Phase 2... Read More

NEW YORK , Aug. 1, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in August: August 8-9: 2023 Wedbush PacGrow Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer and... Read More

Webcast to be Held at 8:00 am ET on August 3, 2023 NEW YORK , July 27, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the second quarter ended June 30, 2023 , including a corporate update, on... Read More

NEW YORK , June 29, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in July: July 6-8 : Symposium 234: Mucosal Immunology – A Translational View into the Clinic. Martina Wirth , Ph.D.,... Read More

NEW YORK , May 30, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June: May 31-June 3 : Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023. Robert J. Fox , MD, Staff... Read More

Preclinical Data Published in the Peer-Reviewed Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator Nurr1 Activation Suggested to Prevent Neurodegeneration Which is Relevant in Multiple Sclerosis, Parkinson's Disease and Beyond NEW YORK , May 17, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small... Read More

Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal Diseases by Promoting Regeneration of Bowel Architecture Interim Results From Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in the Second Half of 2023 $97.1 Million in Cash, Cash Equivalents and Investments Expected to Fund... Read More

Webcast to be Held at 8:00 am ET on May 11, 2023 NEW YORK , May 9, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the first quarter ended March 31, 2023 , including a corporate update, on Thursday,... Read More

IMU-856 is an Orally Available, Systemically Acting, Highly Selective and Potent Small Molecule Modulator of SIRT6 Targets Regeneration of Bowel Epithelium and Restoration of Intestinal Barrier Function Builds on Recently Released Phase 1b Data Showing Beneficial Effects in Celiac Disease Histology, Disease Symptoms, Biomarkers and Nutrient Absorption Virtual ePoster to be Presented Today, May 6, 2023 , During 9:30 am - 4:00... Read More

Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients' Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption Corroborates Hypothesized Ability of IMU-856 to Renew Gut Wall and Restore Gut Health No Safety or Tolerability Issues Detected Conference Call and Webcast to be Held Today, May 4, 2023 at 8:00 am ET... Read More

Thought-Leader in Multiple Sclerosis with Decades of Experience in Academic Medicine and the Pharmaceutical Industry NEW YORK , April 27, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Richard Rudick , M.D., a thought-leader in... Read More

NEW YORK , April 26, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May: May 2-4 : Aegis Virtual Conference. Daniel Vitt , Ph.D., Chief Executive Officer and President of Immunic, will... Read More

50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo 30 mg Once-Daily Dose of Vidofludimus Calcium Demonstrated Statistically Significant Rates of Clinical Remission (p=0.0358) and Endoscopic Healing (p=0.0259) at Week 50 To Focus Resources on High Performing Vidofludimus Calcium and IMU-856 Programs, Immunic Decided to Deprioritize Izumerogant... Read More

NEW YORK , March 2, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in March: March 9 : BioCapital Europe. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will... Read More

Initial Results From Ongoing Part C of Phase 1 Clinical Trial of IMU-856 in Celiac Disease Expected Mid-2023 Interim Results From Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in the Second Half of 2023 $116.4 Million in Cash, Cash Equivalents and Investments Expected to Fund Immunic Into the Fourth Quarter of 2024 Webcast to be Held Today, February 23, 2023 , at 8:00 am ET NEW... Read More

Long-Term Open-Label Treatment With Vidofludimus Calcium Was Associated With a Low Rate of Confirmed Disability Worsening (CDW) Over Time CDW Data Compares Favorably to Historical Trial Data for Currently Available Multiple Sclerosis Treatments NEW YORK , Feb. 22, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused... Read More

Webcast to be Held at 8:00 am ET on February 23, 2023 NEW YORK , Feb. 16, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2022 ,... Read More

Conference Call and Webcast to be Held Today, February 9, 2023 , at 11:00 am ET NEW YORK , Feb. 9, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced that its Celiac Disease R&D Webcast will take place today, February 9, 2023 from 11:00 am to 1:00... Read More

NEW YORK , Jan. 25, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in February: February 1-2 : 31st Pharmacovigilance 2023 . Darius-Jean Namdjou, Ph.D., Head of Regulatory... Read More